Prestudy treatment characteristics and poststudy treatment end points
| Subject age, y . | Histology/no. lines of therapy . | Prim ref to initial induction, Y/N/Last ST . | Status at HDT-ASCT/SPD, cm2 . | DL . | Engraftment neutrophils/ platelets, days post-ASCT . | CRS grade 2-4 . | CRS onset/ resolution, days from CAR T infusion . | NT grade/ characteristic . | NT onset/ resolution, days from CAR T infusion . | B-cell aplasia/ recovery . | Key infections, ≤12 mo post CAR T infusion . | Best response/ PFS, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | tFL/3 | Y/R-DHAX | PET+ PR/32.3 | 1 | 10/15 | None | N/A | Gr 3/Encephalopathy | 4/5 | Persistent hypogamm | N/A | CR/41 |
| 68 | DLBCL/4 | Y/R-gem/ox | PET+ PR/11.5 | 1 | 10/15 | None | N/A | Gr 3/Somnolence | 5/6 | 16 mo | N/A | CR/42 |
| 56 | tMZL/2 | N/R-DHAX | PET+ PR,/5.5 BM involved | 1 | 10/17 | None | N/A | None | N/A | 12 mo | N/A | CR/12 |
| 59 | tFL/DHL/2 | N/R-EPOCH | PET+ PR/18.1 | 2 | 10/39 | Gr 4 | 3/12 | Gr 4/Encephalopathy | 4/12 | 15 mo | Rhinovirus, metapneumovirus, C difficile, RSV | CR/35 |
| 66 | DLBCL/3 | N/R-ICE | PET+ PR/1.7 | 1 | 11/15 | None | N/A | None | N/A | Never hypogamm | N/A | CR/31 |
| 64 | CD5+ DLBCL/2 | N/R-EPOCH | PET+ PR/1.0 | 1 | 11/20 | None | N/A | None | N/A | NE | VRE, RSV | SD/6 |
| 65 | BL/2 | Y/R-IVAC | PET+ PR/2.5 BM involved | 1 | 11/17 | Gr 2 | 10/12 | Gr 3/Encephalopathy | 6/8 | NE | VRE, C difficile | CR/2 |
| 56 | DLBCL/DHL/2 | N/R-ESHAP | PET+ PR/skin, bone | 1 | 23/NRM pre–platelet engraftment | Gr 3 | 4/7 | Gr 3/Seizure | 3/20 | NE | VRE, rhinovirus, mucormycosis | NE/NRM |
| 51 | DLBCL/2 | Y/R-ICE | PET+ PR/157 | 1 | 13/14 | None | N/A | None | N/A | NE | C difficile, metapneumovirus | POD/2 |
| 61 | Blastoid MCL/4 | Y/R-BAc | PET CR, leukemic phase | 1 | 11/14 | None | N/A | Gr 3/Encephalopathy | 5/12 | NE | RSV | POD/2 |
| 75 | Richter/2 | N/i-R-ICE | PET+ PR/29.5 | 1 | 13/24 | Gr 3 | 2/9 | Gr 4/Encephalopathy | 6/8 | 16 mo | N/A | CR/21 |
| 45 | tFL/8 | Y/R-EPOCH | PET+ PR/52.3 | 1 | 11/20 | Gr 2 | 0/3 | Gr 2/Seizure | 1/2 | NE | N/A | SD/2 |
| 61 | DLBCL/2 | N/R-ICE | PET+ PR/23 | 1 | 10/15 | Gr 2 | 2/5 | Gr 4/Aphasia | 5/11 | NE | Rhinovirus | POD/3 |
| 35 | DLBCL/3 | Y/R-IVAC | PET+ PR/9.5 | 1 | 11/17 | None | N/A | None | N/A | NE/lost to follow-up | CMV, rhinovirus | POD/3 |
| 68 | DLBCL/3 | Y/R-gem/ox | PET+ PR/3.6 | 1 | 11/22 | None | N/A | Gr 4/Encephalopathy | 5/14 | 29 mo | C difficile, PJP | CR/14 |
| Subject age, y . | Histology/no. lines of therapy . | Prim ref to initial induction, Y/N/Last ST . | Status at HDT-ASCT/SPD, cm2 . | DL . | Engraftment neutrophils/ platelets, days post-ASCT . | CRS grade 2-4 . | CRS onset/ resolution, days from CAR T infusion . | NT grade/ characteristic . | NT onset/ resolution, days from CAR T infusion . | B-cell aplasia/ recovery . | Key infections, ≤12 mo post CAR T infusion . | Best response/ PFS, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | tFL/3 | Y/R-DHAX | PET+ PR/32.3 | 1 | 10/15 | None | N/A | Gr 3/Encephalopathy | 4/5 | Persistent hypogamm | N/A | CR/41 |
| 68 | DLBCL/4 | Y/R-gem/ox | PET+ PR/11.5 | 1 | 10/15 | None | N/A | Gr 3/Somnolence | 5/6 | 16 mo | N/A | CR/42 |
| 56 | tMZL/2 | N/R-DHAX | PET+ PR,/5.5 BM involved | 1 | 10/17 | None | N/A | None | N/A | 12 mo | N/A | CR/12 |
| 59 | tFL/DHL/2 | N/R-EPOCH | PET+ PR/18.1 | 2 | 10/39 | Gr 4 | 3/12 | Gr 4/Encephalopathy | 4/12 | 15 mo | Rhinovirus, metapneumovirus, C difficile, RSV | CR/35 |
| 66 | DLBCL/3 | N/R-ICE | PET+ PR/1.7 | 1 | 11/15 | None | N/A | None | N/A | Never hypogamm | N/A | CR/31 |
| 64 | CD5+ DLBCL/2 | N/R-EPOCH | PET+ PR/1.0 | 1 | 11/20 | None | N/A | None | N/A | NE | VRE, RSV | SD/6 |
| 65 | BL/2 | Y/R-IVAC | PET+ PR/2.5 BM involved | 1 | 11/17 | Gr 2 | 10/12 | Gr 3/Encephalopathy | 6/8 | NE | VRE, C difficile | CR/2 |
| 56 | DLBCL/DHL/2 | N/R-ESHAP | PET+ PR/skin, bone | 1 | 23/NRM pre–platelet engraftment | Gr 3 | 4/7 | Gr 3/Seizure | 3/20 | NE | VRE, rhinovirus, mucormycosis | NE/NRM |
| 51 | DLBCL/2 | Y/R-ICE | PET+ PR/157 | 1 | 13/14 | None | N/A | None | N/A | NE | C difficile, metapneumovirus | POD/2 |
| 61 | Blastoid MCL/4 | Y/R-BAc | PET CR, leukemic phase | 1 | 11/14 | None | N/A | Gr 3/Encephalopathy | 5/12 | NE | RSV | POD/2 |
| 75 | Richter/2 | N/i-R-ICE | PET+ PR/29.5 | 1 | 13/24 | Gr 3 | 2/9 | Gr 4/Encephalopathy | 6/8 | 16 mo | N/A | CR/21 |
| 45 | tFL/8 | Y/R-EPOCH | PET+ PR/52.3 | 1 | 11/20 | Gr 2 | 0/3 | Gr 2/Seizure | 1/2 | NE | N/A | SD/2 |
| 61 | DLBCL/2 | N/R-ICE | PET+ PR/23 | 1 | 10/15 | Gr 2 | 2/5 | Gr 4/Aphasia | 5/11 | NE | Rhinovirus | POD/3 |
| 35 | DLBCL/3 | Y/R-IVAC | PET+ PR/9.5 | 1 | 11/17 | None | N/A | None | N/A | NE/lost to follow-up | CMV, rhinovirus | POD/3 |
| 68 | DLBCL/3 | Y/R-gem/ox | PET+ PR/3.6 | 1 | 11/22 | None | N/A | Gr 4/Encephalopathy | 5/14 | 29 mo | C difficile, PJP | CR/14 |
BAc, bendamustine and cytarabine; BL, Burkitt lymphoma; BM, bone marrow; C difficile, Clostridium difficile; CMV, cytomegalovirus; CR, complete response; DHAX, dexamethasone, cytarabine, oxaliplatin; DHL, double-hit lymphoma; DL, dose level; EPOCH, etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin); ESHAP, rituximab, etoposide, methylprednisolone, cytarabine, cisplatin; gem/ox, gemcitabine, and oxaliplatin; Gr, grade; hypogamm, hypogammaglobulinemia; i, ibrutinib; ICE, ifosfamide, carboplatin, and etoposide; IVAC, ifosfamide, cytarabine, and etoposide; MCL, mantle cell lymphoma; N, no; N/A, not applicable; NE, not evaluated; NRM, nonrelapse mortality; NT, neurotoxicity; PJP, Pneumocystis jiroveci pneumonia; PR, partial response; Prim ref, primary refractory; R, rituximab; RSV, respiratory syncytial virus; SD, stable disease; SPD, sum of the product of the greatest diameters; ST, systemic therapy; tFL, transformed follicular lymphoma; tMZL, transformed marginal zone lymphoma; VRE, vancomycin-resistant enterococcus; Y, yes.